Felipe Yuji Koyama Azeka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Felipe Yuji Koyama Azeka has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
1 shared publication - Alessandra Valéria de Sousa Faria
Universidade de Sao Paulo Instituto de Ciencias Biomedicas Departamento de Biologia Celular e do Desenvolvimento São Paulo São Paulo Brazil
1 shared publication - Alexander de Moraes Frankiw1 shared publication
- Daniel Delgado Seneor
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
1 shared publication - Helena Panteliou Lima-Valassi
Laboratório de Hormônios e Genética Molecular LIM/42, Disciplina de Endocrinologia, Departamento de Clinica Medica , Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo , São Paulo , Brazil
1 shared publication - Igor Braga Farias
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
1 shared publication
Latest Publications
- Open Access
LRP4-Related Congenital Myasthenic Syndrome: Clinical, Pathophysiological, and Therapeutic Aspects
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.
Open AccessLRP4-Related Congenital Myasthenic Syndrome: Clinical, Pathophysiological, and Therapeutic Aspects
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.